文献速递结核与非结核分枝杆菌

肺结核治疗肺内药代动力学研究方法学系统综述

Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

该系统综述检索Embase和PubMed至2024年7月18日,纳入253项研究,分类梳理了肺内抗结核药物浓度采样、定量与建模方法。采样技术包括痰、组织活检、支气管肺泡灌洗等,定量以LC-MS/MS为主,建模包括群体药代动力学和生理药代动力学。多数方法存在侵入性、复杂性、成本高及缺乏标准化等局限。

要点

  • 痰、组织活检和支气管肺泡灌洗是报告较多的肺内采样方法。
  • LC-MS/MS是生物样本药物定量的金标准,用于67项研究。
  • 群体药代动力学和生理药代动力学模型分别用于32和35项研究。

核心结论

  • 多种肺内药代动力学研究方法各有局限,选择时需综合考虑侵入性、复杂性、成本及标准化程度。
  • 最关键的是所选方法须能充分代表病灶部位药代动力学。

研究设计与样本

  • 系统综述,在Embase和PubMed检索至2024年7月18日,共纳入253项研究。
  • 将方法分为采样技术、定量分析和建模方法三类,涵盖所有肺部疾病类型。

主要发现

  • 采样方法:痰9项、组织活检51项、支气管肺泡灌洗115项、支气管镜微采样8项、支气管吸收1项、微透析12项。
  • 定量方法:LC-MS/MS用于67项研究,正电子发射断层扫描12项,基质辅助激光解吸电离质谱用于肺组织3项。
  • 建模方法:群体药代动力学建模32项,生理药代动力学建模35项。

临床怎么用

  • 优化结核治疗时应依据方法学特征选择能代表病灶部位暴露的肺内药代动力学研究手段。
  • 解读肺内浓度数据时需考虑采样方法的侵入性、复杂性和标准化程度对结果的影响。

局限性

  • 许多已识别方法存在侵入性、复杂性、成本高及缺乏标准化等明显局限。
  • 原文未报告各方法的具体性能比较或推荐优先级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Drug concentrations at the site of disease in pulmonary tuberculosis (TB) remain limitedly available, while adequate exposures of anti-TB drugs in the lungs are required for sterilization of lesions. Intrapulmonary concentration data could benefit TB treatment optimization. We conducted a systematic review to identify methods that can be used for sampling, quantifying, describing and predicting intrapulmonary pharmacokinetics of anti-TB drugs in humans. METHODS: Two systematic search strategies were conducted in databases Embase and PubMed, last searched on 18 July 2024. In total, 253 studies were identified, and their applied methods were classified into three different categories: (i) sampling techniques, (ii) quantitative analysis and (iii) modelling methods. All types of pulmonary diseases were included in the search. RESULTS: Sputum sampling was reported as sampling method in nine studies, tissue biopsy in 51, bronchoalveolar lavage in 115, bronchoscopic microsampling in eight, bronchoabsorption in one and microdialysis in 12 studies. LC-MS/MS, the gold standard for drug quantification in biological samples, was used in 67 studies. Other quantification methods included positron emission tomography, reported in 12 studies and matrix-assisted laser desorption ionization mass spectrometry on lung tissue in three studies. For prediction and description of (pre)clinical intrapulmonary concentration data, population pharmacokinetic modelling was reported in 32 studies and physiologically based pharmacokinetic modelling in 35 studies. CONCLUSIONS: Many of the identified methods are associated with considerable limitations including invasiveness, complexity, cost and lack of standardization. Most importantly, the method of choice must provide adequate representation of site of disease pharmacokinetics. Determining the best approach for studying intrapulmonary pharmacokinetics involves careful consideration of all these factors.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. van der Feltz I, Wen H, Aarnoutse RE, et al. Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology. J Antimicrob Chemother. 2025. PMID: 40808635. doi:10.1093/jac/dkaf274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。